The Biotech Reset: Navigating the Path Forward



Webinar Date/Time: Thursday, May 2nd, 2024 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST

Join us for “The Biotech Reset: Navigating the Path Forward”, an insightful webinar where experts from IQVIA Biotech, IQVIA Institute and IQVIA explore the dynamic reset within the biotech market. Our experts will guide you through this compelling journey, where scientific ambition intertwines with the ever-evolving landscape of clinical research, leveraging strategic partnerships to achieve remarkable outcomes. Don’t miss out on key discussions covering regulatory/strategic drug development, novel trial design and the rise of AI in clinical research!

Register Free:

Event overview

Join us in this insightful webinar as we delve into the dynamic reset seen within the biotech market, exploring the renewed optimism and trends impacting biotech companies and the strategic path to drug development. This discussion illuminates the industry’s transition from adapting in uncertainty to growth within a vibrant era of innovation, with a focus on optimizing R&D spend to quickly deliver robust scientific evidence. Our experts will guide you through this compelling journey where scientific ambition intertwines with the ever-evolving landscape of clinical research, and the importance of leveraging strategic partnerships to achieve remarkable outcomes.

During this webinar you will:
Explore regulatory challenges and opportunities with Project Optimus, diversity plans and data privacy.

  • Gain insights on strategic drug development and how to successfully steer scientific endeavors through uncertain times.
  • Understand the importance of innovative trial designs and master protocols in accelerating R&D processes and reducing development timelines.
  • Discover how Generative AI is revolutionizing clinical trial conduct and how to navigate the inherent risks to optimize your clinical trial.


Meg Hooton
IQVIA Biotech

Megan Hooton, President of IQVIA Biotech, leads the strategic direction of global business, ensuring successful project delivery across all Biotech and MedTech clinical trials. With over three decades of experience in managing global research and development, Meg provides oversight to clinical teams, investigator site services, data services and therapeutic divisions. Her remarkable journey—from nursing to biotech leadership—reflects not only her wealth of operational insights but also her cross-cultural expertise and unwavering commitment to advancing healthcare.

Murray Aitken
Executive Director
IQVIA Institute for Human Data Science

Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, is a globally recognized authority in addressing challenges within the healthcare industry. With a rich 15-year history at IQVIA, he has seamlessly navigated diverse roles spanning healthcare insights, corporate strategy and consulting. Previously, he was a partner at McKinsey & Company in the US and South Korea, for which he focused heavily on Life Sciences. Murray earned his MBA from Harvard and a Masters of Commerce from the University of Auckland. He is a sought-after speaker at international healthcare forums. His insightful perspectives grace esteemed publications including The Wall Street Journal, The Financial Times, Fortune and CNBC.

Keith McDonald
Head of Drug Development Strategy, Regulatory Affairs & Drug Development Solutions

Keith McDonald, a seasoned expert with over 25 years in regulatory affairs and drug development, leads as the Head of Drug Development Strategy at IQVIA. His extensive regulatory authority expertise in clinical trials, marketing authorization approvals and policy development makes him an expert in our industry. His many contributions include providing regulatory authority scientific advice to leading the UK Covid Therapeutics Taskforce, where he shaped policy and secures marketing authorizations.

Register Free:

Related Content
© 2024 MJH Life Sciences

All rights reserved.